Myeloma bone disease: from biology findings to treatment approaches

被引：109

作者：

Terpos, Evangelos ^{[1
]}

Ntanasis-Stathopoulos, Ioannis ^{[1
]}

Dimopoulos, Meletios A. ^{[1
]}

机构：

[1] Univ Athens, Sch Med, Alexandra Gen Hosp, Dept Clin Therapeut, 80 Vas Sofias Ave, Athens 11528, Greece

来源：

BLOOD | 2019年 / 133卷 / 14期

关键词：

DIAGNOSED MULTIPLE-MYELOMA; MARROW STROMAL CELLS; ZOLEDRONIC ACID; RECEPTOR ACTIVATOR; SKELETAL COMPLICATIONS; OSTEOLYTIC LESIONS; CLODRONIC ACID; DOUBLE-BLIND; ACTIVIN-A; DENOSUMAB;

D O I：

10.1182/blood-2018-11-852459

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Bone disease is a cardinal complication of multiple myeloma that affects quality of life and survival. Osteocytes have emerged as key players in the development of myeloma-related bone disease. Along with other factors, they participate in increased osteoclast activity, decreased osteoblast function, and immunosuppressed marrow microenvironment, which deregulate bone turnover and result in bone loss and skeletal-related events. Denosumab is a novel alternative to bisphosphonates against myeloma bone disease. Special considerations in this constantly evolving field are thoroughly discussed.

引用

页码：1534 / 1539

页数：6

共 71 条

[11] Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation [J].

Costa, Federica ;

Toscani, Denise ;

Chillemi, Antonella ;

Quarona, Valeria ;

Bolzoni, Marina ;

Marchica, Valentina ;

Vescovini, Rosanna ;

Mancini, Cristina ;

Martella, Eugenia ;

Campanini, Nicoletta ;

Schifano, Chiara ;

Bonomini, Sabrina ;

Accardi, Fabrizio ;

Horenstein, Alberto L. ;

Aversa, Franco ;

Malavasi, Fabio ;

Giuliani, Nicola .

ONCOTARGET, 2017, 8 (34) :56598-56611

[12] Gfi1 expressed in bone marrow stromal cells is a novel osteoblast suppressor in patients with multiple myeloma bone disease [J].

D'Souza, Sonia ;

del Prete, Davide ;

Jin, Shunqian ;

Sun, Quanhong ;

Huston, Alissa J. ;

Kostov, Flavia Esteve ;

Sammut, Benedicte ;

Hong, Chang-Sook ;

Anderson, Judith L. ;

Patrene, Kenneth D. ;

Yu, Shibing ;

Velu, Chinavenmeni S. ;

Xiao, Guozhi ;

Grimes, H. Leighton ;

Roodman, G. David ;

Galson, Deborah L. .

BLOOD, 2011, 118 (26) :6871-6880

[13] Genetic deletion of Sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth [J].

Delgado-Calle, J. ;

Anderson, J. ;

Cregor, M. D. ;

Condon, K. W. ;

Kuhstoss, S. A. ;

Plotkin, L. I. ;

Bellido, T. ;

Roodman, G. D. .

LEUKEMIA, 2017, 31 (12) :2686-2694

[14] Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple Myeloma [J].

Delgado-Calle, Jesus ;

Anderson, Judith ;

Cregor, Meloney D. ;

Hiasa, Masahiro ;

Chirgwin, John M. ;

Carlesso, Nadia ;

Yoneda, Toshiyuki ;

Mohammad, Khalid S. ;

Plotkin, Lilian I. ;

Roodman, G. David ;

Bellido, Teresita .

CANCER RESEARCH, 2016, 76 (05) :1089-1100

[15]

FULZELE K, 2018, BLOOD S, V132, DOI DOI 10.1182/BLOOD-2018-99-118377

[16] Preclinical Activity of the Oral Proteasome Inhibitor MLN9708 in Myeloma Bone Disease [J].

Garcia-Gomez, Antonio ;

Quwaider, Dalia ;

Canavese, Miriam ;

Ocio, Enrique M. ;

Tian, Ze ;

Blanco, Juan F. ;

Berger, Allison J. ;

Ortiz-de-Solorzano, Carlos ;

Hernandez-Iglesias, Teresa ;

Martens, Anton C. M. ;

Groen, Richard W. J. ;

Mateo-Urdiales, Joaquin ;

Fraile, Susana ;

Galarraga, Miguel ;

Chauhan, Dharminder ;

San Miguel, Jesus F. ;

Raje, Noopur ;

Garayoa, Mercedes .

CLINICAL CANCER RESEARCH, 2014, 20 (06) :1542-1554

[17] Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial [J].

Gimsing, Peter ;

Carlson, Kristina ;

Turesson, Ingemar ;

Fayers, Peter ;

Waage, Anders ;

Vangsted, Annette ;

Mylin, Anne ;

Gluud, Christian ;

Juliusson, Gunnar ;

Gregersen, Henrik ;

Hjorth-Hansen, Henrik ;

Nesthus, Ingerid ;

Dahl, Inger Marie S. ;

Westin, Jan ;

Nielsen, Johan Lanng ;

Knudsen, Lene Meldgaard ;

Ahlberg, Lucia ;

Hjorth, Martin ;

Abildgaard, Niels ;

Andersen, Niels Frost ;

Linder, Olle ;

Wisloeff, Finn .

LANCET ONCOLOGY, 2010, 11 (10) :973-982

[18] Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation [J].

Giuliani, N ;

Colla, S ;

Morandi, F ;

Lazzaretti, M ;

Sala, R ;

Bonomini, S ;

Grano, M ;

Colucci, S ;

Svaldi, M ;

Rizzoli, V .

BLOOD, 2005, 106 (07) :2472-2483

[19] Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation [J].

Giuliani, N. ;

Ferretti, M. ;

Bolzoni, M. ;

Storti, P. ;

Lazzaretti, M. ;

Dalla Palma, B. ;

Bonomini, S. ;

Martella, E. ;

Agnelli, L. ;

Neri, A. ;

Ceccarelli, F. ;

Palumbo, C. .

LEUKEMIA, 2012, 26 (06) :1391-1401

[20] The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation [J].

Guenther, Andreas ;

Gordon, Sharon ;

Tiemann, Markus ;

Burger, Renate ;

Bakker, Frank ;

Green, Jonathan R. ;

Baum, Wolfgang ;

Roelofs, Anke J. ;

Rogers, Michael J. ;

Gramatzki, Martin .

INTERNATIONAL JOURNAL OF CANCER, 2010, 126 (01) :239-246

← 1 2 3 4 5 6 7 8 →